多普勒超声预测类风湿关节炎临床缓解患者成功停用生物DMARDs
本研究纳入119例持续缓解且无影像学进展的RA患者,按标准化方案递减bDMARDs,基线行24关节超声等评估。2年随访显示,IgM-RF阴性及较低多普勒总评分是成功停药的独立预测因素,多普勒总评分每增加1单位成功停药几率降低56%;超声不能预测成功减量。
要点
- 多普勒超声总评分是RA患者2年成功停用bDMARDs的独立预测因素。
- 多普勒总评分每增加1单位,成功停药几率降低56%。
- 超声不能预测bDMARDs成功减量,既往bDMARDs数量可预测减量。
核心结论
- 多普勒总评分是2年随访时成功停用bDMARDs的独立预测因素,每增加1单位成功停药几率降低56%。
- 超声不能预测成功减量。
研究设计与样本
- 纳入119例持续缓解(DAS28-CRP≤2.6)且前一年无影像学进展的RA患者,按标准化方案递减bDMARDs。
- 基线行临床评估、MRI、X线及24关节超声,超声滑膜炎采用OMERACT评分系统对灰阶和多普勒活动分别行0-3分关节水平评分并计算患者水平总评分。
- 2年后评估最终治疗状态,采用逻辑回归分析超声指标对成功减量和停药的预测价值。
主要发现
- IgM-RF阴性(OR=0.29,95%CI:0.10-0.85;P=0.024)和较低24关节多普勒总评分(OR=0.44,95%CI:0.15-0.87;P=0.014)是2年随访成功停用bDMARDs的独立预测因素。
- 多普勒总评分的预测价值独立于MRI表现。
- 既往bDMARDs数量可预测成功减量(OR=0.58,95%CI:0.35-0.91;P=0.018),而超声不能预测减量。
- 临床参数不能预测成功减量或停药。
关键数值与推荐
- 持续缓解定义为DAS28-CRP≤2.6且前一年无影像学进展。
- 超声滑膜炎采用OMERACT评分系统,关节水平灰阶和多普勒活动均评0-3分,计算24关节患者水平总评分。
临床怎么用
- 对持续缓解的RA患者,可参考24关节多普勒超声总评分及IgM-RF状态评估停用bDMARDs的成功可能性。
- 多普勒总评分较高者成功停药几率降低,决策时需结合其他临床因素。
- 超声不适用于预测bDMARDs减量成功,减量决策可参考既往bDMARDs数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the ability of ultrasound to predict successful tapering and successful discontinuation of biological DMARDs (bDMARDs) at the 2-year follow-up in RA patients in sustained remission. METHODS: Patients in sustained remission (DAS28-CRP ≤ 2.6) and with no radiographic progression the previous year tapered bDMARDs according to a standardized regime. A total of 119 of these patients were included in this ultrasound substudy. At baseline, clinical assessment, MRI, X-ray and ultrasound of 24 joints were performed. Ultrasound-detected synovitis was defined and scored 0-3 using the OMERACT scoring system at the joint level for both grey-scale and Doppler activity. Sum scores for each ultrasound modality were calculated for 24 joints at the patient level. The final state of treatment was assessed after 2 years. The predictive value of ultrasound measures for successful tapering and discontinuation at the 2-year follow-up was assessed via logistic regression analyses. RESULTS: Negative IgM-RF [odds ratio (OR) = 0.29, 95% CI: 0.10-0.85; P = 0.024] and lower Doppler sum score of 24 joints (OR = 0.44, 95% CI: 0.15, 0.87; P = 0.014) were independent predictors for successful discontinuation of bDMARDs at the 2-year follow-up. The predictive value of the Doppler sum score was independent of MRI findings. Previous numbers of bDMARDs were predictive of successful tapering (OR = 0.58, 95% CI: 0.35, 0.91; P = 0.018), whereas ultrasound was not. Clinical parameters were not predictive of successful tapering/discontinuation. CONCLUSION: Doppler sum score was an independent predictor for successful discontinuation of bDMARDs at the 2-year follow-up-the odds for achieving successful discontinuation decreased by 56% per one-unit increase in Doppler sum score. Ultrasound could not predict successful tapering.
引用
- Terslev L, Brahe CH, Hetland ML, et al. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission. Rheumatology (Oxford). 2021. PMID: 33748831. doi:10.1093/rheumatology/keab276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。